Tiziana to join ACTRIMS-ECTRIMS meeting in Toronto on foralumab programs

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced on October 21, 2026 that members of its management and business development team will take part in the 10th Joint ACTRIMS-ECTRIMS Meeting, called MSToronto2026, running from October 21 to 23, 2026 at the Metro Toronto Convention Centre.¹ The company described the gathering as a premier international scientific forum that brings together researchers, clinicians, and industry leaders focused on advances in multiple sclerosis and related neuroinflammatory disorders.¹

At the conference, Tiziana representatives plan to discuss the company's clinical work, including the INFORM-MS trial (NCT06292923) testing intranasal foralumab in non-active secondary progressive multiple sclerosis, along with ongoing studies in Alzheimer's disease, multiple system atrophy, and ALS, plus potential scientific and business partnerships.¹

CEO Ivor Elrifi said the meeting offers a chance to connect with researchers and potential partners as the company advances its anti-CD3 antibody candidate, describing intranasal foralumab as designed to induce regulatory T cells and reduce microglial activation in neuroinflammatory and neurodegenerative diseases.¹

Regarding clinical progress, the company said 14 patients with non-active secondary progressive MS have been dosed so far in an open-label Expanded Access Program (NCT06802328), with all patients showing either improvement or stability of disease within six months.¹ Separately, the drug is also being tested in a dose-ranging Phase 2a trial under the same registry number, NCT06292923, as well as in additional Phase 2 studies covering Alzheimer's disease and multiple system atrophy, according to the release. The company stated that intranasal foralumab is currently the only fully human anti-CD3 monoclonal antibody in clinical development.¹